BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New CFO, Corporate Secretary

Company: RYAH Group Inc. (RYAH)
Category: News

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced the appointment of a new chief financial officer and corporate secretary. The company named François C. Desrosiers, B. Com (Spec.) and FCSI, as Rryah CFO and corporate; the appointment is subject to approval  by the Canadian Securities Exchange (“CSE”). Desrosiers brings impressive experience in senior executive leadership roles to his new role with RYAH. He has served as cofounder, president, CEO and director at Northcore Resources Inc.; corporate secretary and officer at Prime Blockchain Inc., whic merged with RYAH Group; and founder, president, CEO and director at AntOro Resources. He also served in key executive roles at Melkior Resources Inc., NIKRON Technologies Inc. and Orbite Exploration VSPA. In addition, he has served as consultant for a number of private and public companies and was a registered representative and officer at securities brokerage companies in Montreal and Ottawa. “RYAH is extremely fortunate to have someone of François’ high caliber and extensive experience to contribute to our financial leadership and success,” said RYAH CEO Dr. Dave Richards in the press release.

To view the full press release, visit https://ibn.fm/4AF5t

About RYAH Group Inc.

RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches and pens. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping doctors and patients personalize treatments, control dosages, and better predict and monitor outcomes. The data and derived insights are also highly valuable for hospitals, clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers and pharmaceutical companies, and to monitor and manage formulation effects on patients based on dosages, strains, demographics, specific conditions and a range of other factors. Exciting new directions under CEO Dr. David Richards’ leadership include R&D in the realm of blockchain, NFTs and cryptocurrency that will pave the way toward successful commercialization of RYAH’s big-data assets. Through the above along with a relentless focus on innovation and track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio. For more information about the company, please visit www.RyahGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050